Equity by Design in Clinical Research: Cancer Trials
Welcome to EQUITY BY DESIGN IN CLINICAL RESEARCH: CANCER TRIALS, a virtual training course communicating an understanding of, and training on best practices for, diversity, equity, and inclusion (DEI) of underrepresented populations in clinical trials. The course is intended to aid cancer centers in improving their ability to enroll underrepresented participants in clinical research and to develop mechanisms for ongoing sustainability of DEI in clinical research. Ethical and regulatory considerations will be included, and practical guidance for commitment, communication, partnership, and conduct will be emphasized.
This virtual course is a six-part series. One module will be presented each week from 4:30-6:00pm EST (on alternating Tuesdays and Thursdays) for six weeks. All modules will begin with 45 minutes of instruction, followed by 45 minutes of discussion with leaders in the field. Attendees are encouraged to attend all sessions but are not required to do so.
Module 1 (3/8/22): Commitment to DEI
Module 2 (3/17/22): Community Engagement and Representation
Module 3 (3/22/22): Study Planning and Communications
Module 4 (3/31/22): Study Conduct
Module 5 (4/5/22): Workforce Development
Module 6 (4/14/22): Accountability, Advocacy, and Justice
This activity is intended for professionals and staff, leadership, and administration involved in Medical Oncology and Hematology with particular relevance to clinical research. The audience includes investigators, practicing providers, clinical trialists, clinical trials office staff, nurse practitioners, nurses, research nurse specialists, physician assistants, clinical research coordinators, and other frontline staff; Regulatory/IRB committee members, and others with basic experience conducting clinical trials.
Please see the individual modules. Each module has detailed learning objectives.
The Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard, The Center for Cancer Equity and Engagement at Dana-Farber/Harvard Cancer Center
and Mass General Brigham
For questions or assistance with any special needs regarding the training series, please contact the MRCT Center at: MRCT@bwh.harvard.edu
- Barbara Bierer, MD (Course Director), Professor of Medicine (Pediatrics) at Harvard Medical School and Brigham and Women’s Hospital, is the faculty director of the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) and a hematologist/oncologist. She is the Director of the Regulatory Foundations, Ethics and the Law Program of the Harvard Clinical and Translational Science Center and the Director of Regulatory Policy, SMART IRB.
- Timothy Rebbeck, PhD, is the Vincent L. Gregory, Jr. Professor of Cancer Prevention, Epidemiology, Harvard T.H. Chan School Of Public Health; Dr. Rebbeck is also a Professor of Medical Oncology at Dana-Farber Cancer Institute.
In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Mass General Brigham designates this live activity for a maximum of 1.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.